April 10, 2023
1 min read
Save
Celanese’s drug delivery platform to be used with iDose TR
Key takeaways:
- Celanese and Glaukos entered into an agreement for the VitalDose drug delivery platform to be used with the iDose TR.
- VitalDose has the potential to provide continuous dosing.
Celanese has entered into an agreement with Glaukos to supply the VitalDose drug delivery platform for Glaukos’ iDose TR, according to a press release.
The iDose TR is a microinvasive intraocular implant designed to continuously deliver a travoprost formulation to lower IOP in those with primary open-angle glaucoma or ocular hypertension. VitalDose has the potential to help provide continuous dosing, which can reduce issues with patient compliance and adherence.
Image: Adobe Stock
According to the release, VitalDose provides “reliable, controlled-release performance and has a long history of use in approved parenteral drug products in the United States and Europe.”
Glaukos submitted a new drug application for iDose earlier this year.
Published by:
Read more about